Loading stock data…
Waystar Holding Corp. (WAY)
$19.98+0.08 (+0.40%)
After Hours$19.98+0.00 (+0.00%)· Last close Jun 29
Waystar Holding Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Waystar Holding Corp. in the Healthcare sector is trading at $19.98 with a market capitalization of $3.7B. Wall Street consensus targets $33.65 (23 analysts), implying a +68.4% move over the next 12 months. The stock is currently near its 52-week low of $17.26, remaining 30.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +68.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $313.87M↑ | $303.54M↑ | $268.65M↓ | $270.65M↑ | $256.44M |
| Gross Profit | $216.84M↑ | $210.90M↑ | $183.51M | $183.61M↑ | $173.09M |
| Operating Income | $80.47M↑ | $59.02M↓ | $60.23M↓ | $64.85M↓ | $65.21M |
| Net Income | $43.28M↑ | $19.99M↓ | $30.65M↓ | $32.18M↑ | $29.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
Waystar Holding Corp. develops a cloud-based software solution for healthcare payments. Its platform offers financial clearance, patient financial care, claim and payer payment management, denials prevention and recovery, clinical integrity and reven...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.14
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.20%
Volume
Today's trading volume
1.77M
Recent News
Share Buyback Program Reflecting Favorably on Waystar Holding’s (WAY) Future Prospects
Waystar Holding Corp. (NASDAQ:WAY) is one of the 10 technology stocks offering more than 50% upside. On May 19, Waystar Holding Corp. (NASDAQ:WAY) announced its Board of Directors authorized a stock repurchase plan for up to $200 million of common stock. These shares can be repurchased from time to time. According to this plan, there […]
TBRG vs. Waystar: Which Healthcare RCM Stock Is the Better Bet Now?
WAY's AI-driven RCM growth and strong Q1 results stand out, while TruBridge trades near its pending buyout price with limited upside.
Does Waystar Holding's (WAY) New Buyback Sharpen the AI Healthcare Payments Thesis or Cloud the Story?
Waystar Holding Corp. announced in May 2026 that its Board authorized a share repurchase program of up to US$200,000,000 of common stock, reinforcing management’s capital allocation priorities following recent earnings strength. This move comes as investors and analysts have highlighted Waystar’s cloud-based, AI-powered revenue cycle platform and the benefits of its Iodine Software acquisition, framing buybacks as one more lever in an increasingly software- and AI-focused healthcare payments...
Waystar Holding Corp. (WAY) Plummeted Amid Fears Around AI Disruption
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Growth Fund”. A copy of the letter can be downloaded here. The US equity market started 2026 with volatility due to trade policy uncertainty and geopolitical risks. Initial optimism from domestic company confidence and the Federal Reserve easing waned following increased […]
AI Is Coming for Pharmacy Benefit Managers: Potential Winners and Losers
Pharmacy benefit managers (PBMs) sit at the chokepoint of U.S. drug distribution. They negotiate rebates, design formularies, adjudicate claims, and steer patient adherence. Modern artificial intelligence (AI) is designed to compress each of these high-volume, rules-driven processes. As autonomous prior authorization, real-time formulary optimization, and AI-driven rebate analytics scale, the Big Three PBMs face a ... AI Is Coming for Pharmacy Benefit Managers: Potential Winners and Losers